Skip to main content

WegovyTM (semaglutide) injection

Wegovy™ (semaglutide) injection is initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased at 4-week intervals, following the dose escalation schedule, until a dose of 2.4 mg once weekly is reached. For more information about the dose escalation schedule for Wegovy™, please see the Prescribing Information.

Wegovy™ (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. The response(s) are not intended to offer recommendations for administering Novo Nordisk products in a manner inconsistent with approved labeling. To access the Prescribing Information for Novo Nordisk products, please click here.

Search for Letters

Find documents for this product by entering your search terms in the box below.

 

Text: double click to edit.

Have a Question?

Request information directly from the Novo Nordisk
Medical Information department.